{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Nektar Therapeutics
Nektar Therapeutics Hits New 52-Week High of $61.15, Up 233.78%
Nektar Therapeutics achieved a new 52-week high of USD 61.15 on September 24, 2025, reflecting a significant increase in stock performance over the past year. With a market capitalization of USD 868 million, the company operates at a loss but shows strong return on equity and notable financial leverage.
Nektar Therapeutics Hits New 52-Week High of $61.06, Up 229.74%
Nektar Therapeutics has achieved a new 52-week high, reflecting a substantial increase over the past year, significantly outpacing broader market growth. With a market capitalization of USD 868 million, the company exhibits strong profitability metrics but remains loss-making, indicating a volatile yet promising position in the biotechnology sector.
Nektar Therapeutics Hits New 52-Week High of $59.58, Soars 205%
Nektar Therapeutics achieved a new 52-week high of USD 59.58 on September 19, 2025, reflecting a 205.06% increase over the past year. The company, with a market cap of USD 868 million, shows strong financial metrics but remains loss-making, highlighting its unique position in the biotechnology sector.
Is Nektar Therapeutics technically bullish or bearish?
As of September 5, 2025, Nektar Therapeutics shows a bullish technical trend, supported by strong moving averages and Bollinger Bands, despite mixed RSI readings and underperformance over longer periods compared to the S&P 500.
Is Nektar Therapeutics overvalued or undervalued?
As of August 2019, Nektar Therapeutics is considered overvalued and risky due to high valuation ratios, negative financial metrics, and significant long-term stock decline despite recent short-term gains.
Nektar Therapeutics Hits Day High with 15.06% Surge in Stock Price
Nektar Therapeutics has seen significant stock activity, with a notable rise today and impressive gains over the past week and month. Despite these short-term successes, the company faces challenges such as declining net sales, operating losses, and a negative EBITDA, raising concerns about its long-term fundamentals.
Nektar Therapeutics Hits New 52-Week High of $58.81, Up 225%
Nektar Therapeutics has achieved a new 52-week high of USD 58.81, reflecting a significant growth trajectory with a 225.09% increase in stock price over the past year. Despite its current loss-making status, the company boasts a market capitalization of USD 868 million and an impressive return on equity of 496.67%.
Nektar Therapeutics Hits New 52-Week High of $52.75, Up 182.54%
Nektar Therapeutics has achieved a new 52-week high, reflecting significant growth in the Pharmaceuticals & Biotechnology sector. With a market capitalization of USD 868 million, the company has shown impressive performance over the past year, despite operating at a loss and having unique financial metrics.
Is Nektar Therapeutics overvalued or undervalued?
As of August 9, 2019, Nektar Therapeutics is considered overvalued and risky due to a high price-to-book ratio of 9.02, a negative return on equity of -860.22%, and poor performance compared to peers, with a year-to-date return of -31.61% versus the S&P 500's 2.44%.
Is Nektar Therapeutics technically bullish or bearish?
As of June 10, 2025, Nektar Therapeutics shows a mildly bearish trend, with daily moving averages and weekly Bollinger Bands indicating weakness, despite a mildly bullish MACD on longer time frames.
Who are in the management team of Nektar Therapeutics?
As of March 2022, the management team of Nektar Therapeutics includes Robert Chess (Independent Chairman), Howard Robin (President and CEO), Roy Whitfield (Lead Independent Director), and several Independent Directors: Jeff Ajer, Myriam Curet, Karin Eastham, and R. Scott Greer. They oversee the company's strategic direction and operations.
What does Nektar Therapeutics do?
Nektar Therapeutics is a biopharmaceutical company focused on developing medicines for unmet medical needs, with a recent market cap of $108.31 million and quarterly net sales of $10 million, but reporting a net loss of $51 million. The company has no dividend yield and significant negative return on equity.
How big is Nektar Therapeutics?
As of Jun 18, Nektar Therapeutics has a market capitalization of 108.31 million and reported net sales of 87.25 million with a net profit of -133.04 million over the latest four quarters. Shareholder's funds are 60.74 million, and total assets amount to 303.85 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
